Alfredo Addeo, MD, is a Consultant Medical Oncologist at the University Hospital of Geneva, Switzerland. He is the author of numerous national and international peer-reviewed publications in renowned scientific journals, including first- and last-author publications in the Journal of Clinical Oncology, Annals of Oncology and Lancet Oncology. He has acted as a reviewer for several international scientific journals, including Journal of Thoracic Oncology and JAMA Oncology, and is an associate editor for Frontiers in Thoracic Oncology and guest editor for Precision Cancer Medicine. Dr. Addeo is an active ESMO member and a member of the EORTC lung group. He actively participates in ETOP (European Thoracic Oncology Platform) and SAKK (the Swiss Group for Clinical Cancer Research) and is a researcher and co-investigator of several national and international studies.
Don’t miss the WestWind podcast with Dr. Jack West hosting Dr. Addeo to learn more about his path and challenges from Italy over UK to Switzerland.
He was trained and received his doctorate in Italy from the University School of Medicine in Turin. After his residency, he worked for another 4 years in Turin as a Consultant Oncologist. From 2010 to 2017 he further sharpened his interest in thoracic malignancies in the UK. First at the United Lincolnshire Hospital NHS Trust and later at the University Hospital Bristol, Dr. Addeo also took on the role as senior lecturer in Medical Oncology. As an active member of the NCRI Mesothelioma Working Group, he has also participated in several national and international NCRI drug studies. Dr. Addeo’s research continues to focus on drug development and translational aspects of precision medicine, immunotherapy and side effects, particularly in small and non-smal cell lung cancer (NSCLC) as well as melanoma.
During his time in the UK, Dr. Addeo developed further research interests in liquid biopsies, ctDNA analysis, and tumor mutation burden (TMB) in blood samples. For his research activities in this field he received a grant for a research proposal, which is still ongoing.
In September 2017, Dr. Addeo moved to Geneva, where he received the post of medical oncologist with a primary responsibility for Thoracic Malignancies.
Solange Peters, MD, PhD, is Professor and chair of Medical Oncology as well as the Thoracic Malignancies programme in the department of oncology at the University Hospital of Lausanne, Switzerland. She has authored numerous peer-reviewed manuscripts and book chapters, and serves as deputy editor of the Journal of Thoracic Oncology, and on the editorial board of several other oncology journals. Professor Peters is active in the educational programs of the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC), notably working as the current editor of the ESMO lung cancer clinical practice guidelines. She is the Chair of ESMO Women for Oncology Committee, and she is the youngest ESMO President-elect ever, for a mandate in 2020-2021. She was also a member of the IASLC board of directors, and acts as vice president of the Swiss Group for Clinical Cancer Research lung group. She received both her doctorate in medicine and PhD from the University Hospital of Lausanne, Switzerland. After completing her clinical education in medical oncology and molecular biology in Switzerland and Italy, Professor Peters has specialized in thoracic tumors, lung cancer, and pleural tumors.
Professor Peters is currently in charge of teaching and patient care in the area of Thoracic Malignancies in the department of oncology of Lausanne University, where she is building a translational programme in collaboration with the molecular oncology laboratory directed by Dr. Hanahan at the Swiss Federal Institute of Technology in Lausanne and the Ludwig Institute. Professor Peters’ main field of interest is new biomarker discovery and validation in preclinical and clinical settings. She is also strongly involved and interested in multimodality trial building for locally advanced non-small cell lung cancer (NSCLC), as well as cancer immunotherapy.
Professor Peters’ current research projects are focused on multimodality stage III NSCLC treatment strategies, immunotherapy in limited small cell lung cancer and advanced thymic malignancies, advanced NSCLC, ALK inhibitors, HER2 inhibitors, as well as immunotherapy combinations and new immunomodulating treatments across thoracic malignancies. She acts as the local principal investigator (PI) for lung trials opened at Lausanne Cancer Centre, focused on phase I predictive biomarkers and thoracic malignancies immunotherapy, and is a co-PI of several other trials. Additionally, she acts as the scientific coordinator of the European Thoracic Oncology Platform (ETOP).
|(Central European Time)|
|13.00||Welcome & introduction||S. Peters &
|13.10||The power of social media in Oncology: what we can learn from our virtual peers||G. Morgan|
|13.30||Treatment standards in non-oncogene addicted NSCLC before COVID19||M. Pérol|
|13.50||How can we treat patients with lung cancer during the SARS-CoV-2 pandemic||G. Banna|
|14.10||COVID19 & lung cancer: treatment & outcomes from a Spanish cohort||A. Calles|
|14.30||Radiotherapy in lung cancer during the COVID-19 era||A. Durham|
|14.50||Mesothelioma: new therapeutic strategies and future perspectives for a difficult disease with a heavy social burden||A. Curioni|
|15.40||Small cell lung cancer (SCLC): Treatment challenges and a glimpse into the development of new targets||S. Liu|
|16.00||Personalized Medicine with IO: can we tailor immunotherapy options to patients?||J. Bauml|
|16.20||Actionable mutations on the horizon: up and coming agents in targeted therapies||C. Rolfo|
|16.40||Tailoring targeted therapies: what TKI is suitable for what patient?||H. West|
|17.00||Integrating immunotherapy into localized NSCLC||S. Patel|
|17.20||Final Questions and Wrap Up||A. Addeo & S. Peters|
International Lung Cancer SummitFollow
Leading MedOncs in Thoracic Cancer discuss recent discoveries & advances for the treatment of lung cancer at the ILCS. Register @ https://t.co/0ixI9mMVzl
SPLENDOUR: Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC @JTOonline @ETOP_eu @EORTC @gecp_org @SAKK_ch @peters_solange @MdCurioni @BenjaminBesseMD @bmassutis https://www.sciencedirect.com/science/article/abs/pii/S1556086420304810
OncoViews on ESMO 2020 - Lung Cancer
September 23, 5 PM GMT+2
Christine M. Lovly
#webinar #webinars #médico #médica #oncology #oncologia
Very nice lecture and discussion.
Thank you for giving me the opportunity to review and learn.
#ESMO20 was a great success! Recognising success means to also recognise who is behind it, incl. those hidden behind the scenes. I want to thank the @myESMO staff – without you all this would have not happened. Thank you! 🌹
Thank you @Alfdoc2 for the great moderation and wonderful atmosphere 🌞 with @christine_lovly ! It was a pleasure and honour to discuss with you the latest data from #ESMO20 on #lungcancer #LCSM @OncoViews @OncoAlert https://twitter.com/Alfdoc2/status/1308870127643959297
I want to thank @OncoViews for being such a great educational platform. More done and more to do. @MdCurioni @christine_lovly and I spent more than 1 h chatting and discussing and it was fantastic. I would have loved to do it in person but 4 the time being will do like that
We had a fantastic session yesterday on latest treatment options for lung cancer! Thank you to all our #OncoViewers & for the great discussions with @Alfdoc2, @MdCurioni & @christine_lovly 👏
Missed it or would simply like to watch again?
Check in at http://oncoviews.com
We are continuing our production for #BeyondTheJournal, and just concluded an awesome session with Dr. Gil Morgan @weoncologists @OncoAlert w/ @JackWestMD. We look forward to sharing these with all of you, stay tuned! #MedTwitter #SocialMedia #Oncology #LCSM
#OncoAlert Online @TheLancetOncol are results from NADIM: single arm phase II trial of neoadjuvant chemotherapy + nivolumab for resectable NSCLC. We saw updates at @IASLC #WCLC19 - here we see results with median f/u of 2 years. #LCSM
@ChristianRolfo Director of Thoracic Oncology and early Clinical Trials at @UMGCCC will deliver keynote titled "IASLC Consensus Statement | 2020 Update." Register for access to all scientific data presented at @IASLC #LiquidBiopsy20 https://lb2020.iaslc.org/. #LCSM #IASLC
🚭 Don’t smoke‼️☹️ 🚬 1st cause of #LungCancer & Synergistic with other risk factors (radon, diesel, etc) #LCSM #OncoAlert @_SEOM @myESMO 🕹 Great illustrative video @saraillamas https://www.instagram.com/p/CEeCRCwKFSI/?igshid=mkzdif42poxx
Dr. Pasi Jänne, Dir. of the Lowe Center for Thoracic Oncology at @DanaFarber & Prof. of Medicine at @harvardmed will give keynote "Personalizing Lung Cancer Treatment" on Oct. 2 at #LiquidBiopsy20. Register now https://lb2020.iaslc.org #LCSM @ChristianRolfo @MEArcila
Just Out📣 @TheLancetOncol 📰
NADIM supports addition of neoadj nivolumab🧪to platinum-based #chemotherapy in resectable stage IIIA #NSCLC #LungCancer #LCSM
✅Neoadj chemoimmuno COULD change perception from potentially lethal to curable
For sponsoring requests, please contact us at email@example.com